VK-II-86
CAS No. 955371-84-3
VK-II-86( —— )
Catalog No. M25010 CAS No. 955371-84-3
VK-II-86 is a non-β-blocking carvedilol analog. It prevents ouabain-Induced cardiotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 277 | In Stock |
|
| 10MG | 417 | In Stock |
|
| 25MG | 743 | In Stock |
|
| 50MG | 1115 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVK-II-86
-
NoteResearch use only, not for human use.
-
Brief DescriptionVK-II-86 is a non-β-blocking carvedilol analog. It prevents ouabain-Induced cardiotoxicity.
-
DescriptionVK-II-86 is a non-β-blocking carvedilol analog. It prevents ouabain-Induced cardiotoxicity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number955371-84-3
-
Formula Weight420.5
-
Molecular FormulaC25H28N2O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (237.81 mM)
-
SMILESCOC1=CC=CC=C1OCCNCC(CCOC2=CC=CC3=C2C4=CC=CC=C4N3)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
WST-1
WST-1 is a cytotoxic, water-soluble tetrazolium salt that induces intracellular mitochondrial dehydrogenases to undergo NADH-dependent enzymatic reactions, releasing water-soluble methylbenzene products.
-
(Glu2)-TRH
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS.
-
SPR741
SPR741, formerly NAB741 (12), is a cationic peptide derived from polymyxin B and is one such potentiator molecule that is under development for the treatment of serious Gram-negative bacterial infections.
Cart
sales@molnova.com